Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus and Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma
NCT02254239Phase 1Terminated
- Sponsor
- Mayo Clinic
- Start
- Feb 2016
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of everolimus in Hodgkin lymphoma (HL), sponsored by Mayo Clinic. Primary endpoint: Maximum Tolerated Dose at 21 days. Started Feb 2016; status: terminated.
02
Drugs
everolimus
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT02254239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02254239.